Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 16Recruiting 5Withdrawn 2Terminated 2Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Melanoma 5Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × Vemurafenib × Clear all
NCT01765556 2016-11-02

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Hoffmann-La Roche

Phase 1 Withdrawn
Dermatologic

Melanoma, Neoplasms

NCT01974258 2016-11-02

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

Hoffmann-La Roche

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡